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Abstract
Background:  To determine whether estradiol-to-progesterone (E2/P) ratios at the time of
embryo transfer (ET) have an effect on implantation and pregnancy in IVF cycles.
Methods: 239 women consecutively treated by IVF or ICSI were retrospectively analyzed and
early luteal serum E2 and P were measured on the day of ET. Transfer occurred after a variable in
vitro culture period ranging from 4–7 days after ovulation induction (OI). Following ET, serum E2/
P ratios were calculated for clinical pregnancies, preclinical abortions and non-coneption cycles.
Results: Receiver-operator curve analysis demonstrated that the E2/P ratio could differentiate
between clinical pregnancies and non-pregnant cycles (area under the curve on OI +4 days = 0.70;
95% CI = 0.60–0.80; p = 0.003, on OI +5 days = 0.76; 95% CI = 0.64–0.88; p = 0.001, OI +7 days
= 0.85; 95% CI = 0.75–0.96; p < 0.0001).
Conclusion:  These retrospective data may hold prognostic value regarding endometrial
receptivity as reflected by E2/P measurements and may help improve IVF treatment outcome.
Further prospective studies should be undertaken to confirm these obersveration.
Background
Progesterone (P) and estradiol (E2) are required for suc-
cessful conception, both to prepare the endometrium for
blastocyst implantation and pregnancy. During IVF-ET,
controlled ovarian hyperstimulation results in excessive
follicular development and supraphysiologic serum con-
centrations of E2 and P. Such derangements raised con-
cerns about the impact of such abnormalities on the luteal
phase and a possible adverse impact on endometrial tis-
sue [1-3]. E2  initiates hypertrophy and hyperplasia of
endometrial epithelia, but its role in the luteal phase
remains poorly understood. How E2 influences endome-
trial synchronization and blastocyst implantation is also
not well described [4-6]. In contrast, the role of P in the
luteal phase is better examined Csapo et al [7,8] showed
that luteectomy leads to miscarriage in almost every case
if performed before seven weeks of gestational age. P
transforms the E2-prepared endometrium into a secretory
tissue and creates a hospitable environment for embryo
attachment [9].
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Although previous research has established that E2 and P
regulate events leading to implantation, relatively little is
known about their relative proportion in maternal serum
during the early luteal phase. In the present study, we ret-
rospectively compared the E2/P ratio in the luteal phase in
women undergoing superovulation for IVF-ET who had a
successful implantation with those who failed to conceive
after such treatment.
Patients and methods
Records from 239 infertile patients attending the assisted
reproductive unit at the Department of Obstetrics and
Gynecology, General Hospital St. Poelten, Austria, from
January 2003 to May 2004 were reviewed. Only those
who completed the IVF/ICSI – ET cycle and had a preg-
nancy test in our laboratory 18 days after ovulation induc-
tion were included. Mean (± SD) patient age in this study
population was 32.7 ± 3.97 years (range 18–41). Fourty-
nine clinical pregnancies were achieved in 239 cycles (118
conventional IVF and 121 ICSI) after ET and a clinical
pregnancy rate of 21.0 % per ET was determined. When
stratified by diagnostic category, 106 patients had tubal
disease (44.4%), 38 had endometriosis (5.4%), 13 had
polycystic ovary syndrome (15.9%), 18 had unexplained
infertility (7.5%), and 64 had male factor infertility
(26.8%). For some patients, more than one infertility fac-
tor was assigned. ICSI was indicated for prior failed IVF
fertilization(s) and male factor infertility as defined by
severe semen abnormalities where semen analysis showed
a sperm count of <20 M/mL. Patients were selected on the
basis of a stimulation protocol from a computer-gener-
ated random number table.
In this study, two controlled ovarian hyperstimulation
protocols were used: 61 women were treated with a con-
ventional long protocol using a combination of intranasal
buserelin (Suprecur®, Hoechst, Frankfurt, Germany) at a
dose of 0.15 mg, 3 times daily from the midluteal phase
of the cylce preceding the treatment cycle followed by
rFSH (Puregon®, N.V. Organon, Oss, The Netherlands).
Additionally, 178 women were treated with rFSH (Pure-
gon®, N.V. Organon, Oss, The Netherlands) starting on
day 2 of the menstrual cycle. From day 6–7 of the index
cycle, 0.25 mg of ganirelix (Orgalutran®, N.V. Organon,
Oss, The Netherlands) was administered daily as a subcu-
taneous injection up to and including the last day of rFSH
administration. Serum concentration of E2 (pg/mL) and
transvaginal ultrasound were used to monitor follicular
growth. Ovulation was triggered by i.m. administration of
10,000 IU of hCG (Profasi®, Serono, Switzerland) when
the mean follicular cohort diameter reached 19 mm. Ovu-
lation induction (OI) was the beginning of the luteal
phase and was designated as OI day 0. Oocyte retrieval
was carried out transvaginally under ultrasound guidance
34–36 h after OI. Previous studies have described ICSI
and IVF procedures in detail [1,10]. Fertilization rate was
defined as the proportion of oocytes resulting in two pro-
nuclei (2pn) formation; only metaphase II oocytes were
counted in IVF/ICSI cycles. Transfer was carried out 4 days
after OI (OI +4 days), 5 days after OI (OI +5 days) or 7
days after OI (OI +7 days). Normally cleaved embryos
were replaced under ultrasound guidance using a K-soft
5001 catheter (Cook, Queensland, Australia). All patients
had luteal support with Utrogestan vaginal capsules 2 ×
100-mg capsules, twice a day (Viatris Pharma, Vienna,
Austria) beginning on the day of embryo transfer. Patients
with less than an E2 level <1500 pg/mL on the day of
oocyte retrieval recieved only one additional luteal sup-
port of 1500 IU hCG (Pregnyl®, N.V. Organon, Oss, The
Netherlands). Venous blood samples were collected on
the morning of oocyte retrieval and on the day of ET.
Serum E2 and P concentrations were measured via electro-
chemiluminescence immunoassay "ECLIA" (Roche Elec-
sys, Roche Diagnostics, Mannheim, Germany). For E2,
inter- and intra-assay coefficients of variation on high
concentration control (high E2: 1018 pg/mL) were 2.8
and 1.9%, respectively. For P (high P: 30.2 ng/mL), the
inter- and intra-assay coefficients of variation were 5.5
and 2.7%, respectively. The ratio of E2/P was calculated for
conception and non-conception cycles as defined below.
Outcome measures
Single serum β-hCG measurement was performed on
specimens obtained by peripheral veinpuncture 18 days
after OI. Transvaginal ultrasound examination was per-
formed at 8 weeks' gestation to identify clinical preg-
nancy, defined as the presence of a cardiac action on
ultrasound scan. A conception established only on bio-
chemical serum data was defined as preclinical abortion
[11]. Supplementary P was continued until 8 weeks of ges-
tation.
Statistical analysis
Statistic Package for Social Sciences (SPSS v 10.0 for Win-
dows, Chicago, IL) software was used for data analysis.
Statistical significance was assessed using the Student t-
test and χ2 test as appropriate. One-way analysis of vari-
ance (ANOVA) was used to test significant difference
between groups. Hormonal data were log-transformed to
correct for skewness prior to statistical analysis and values
in the three groups were compared using the nonparamet-
ric Kruskal-Wallis test. Significance was interpreted as p <
0.05. All data were presented as mean ± SD.
From this, receiver operating characteristic (ROC) curves
were developed to depict probability of true-positive
results (sensitivity) as a function of false-positive results
(1 -specificity). Sensitivity and specificity were calculated
for all determined ratios of the decision axis and com-
bined with the area under the curve (AUC). The AUC (sen-Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1 http://www.jexpclinassistreprod.com/content/4/1/1
Page 3 of 6
(page number not for citation purposes)
sitivity/1 - specificity) format approach was used to
confirm test adequacy (AUC near 1) or inadequacy (AUC
near 0.5).
Results
The means (±SD) of various clinical parameters for clini-
cal pregnancies, preclinical abortions and for non-concep-
tion cycles are presented in Table 1. Mean basal FSH
(measured on cycle day 2–4) was 7.39 ± 2.6 IU/L (range
3.0–14). Mean duration of gonadotrophin (rFSH) admin-
istration was 10 ± 1.2 days (range 7–13) for the long pro-
tocol and 10 ± 1.4 days (range 7–14) for the GnRH-
antagonist protocol. The mean peak E2 was 1174.7 ±
828.0 pg/mL (range 164–7196), and mean number of
retrieved oocytes was 8.87 ± 6.09 (range 1–28). Only one
case of severe OHSS was encountered. The mean number
of pre-embryos replaced was 2.5 ± 0.8 (range 1–4). The
clinical pregnancy rate per ET was 18.0% (OI +4 days),
21.5% (OI +5 days) and 43.3% (OI +7 days). Fourty-nine
(21.0%) had a viable intra-uterine pregnancy at 8 weeks
gestations, 27 (11.2%) had an abnormal pregnancy (pre-
clinical abortion) and 163 (67.8%) failed to conceive.
There was no influence of the method of fertilization (IVF
or ICSI) on the outcome (clinical pregnancies p = 0.668,
preclinical abortions p = 0.564 and non-conception cycles
p = 0.583; χ2 test).
There were significant differences when related to the age
of the patient (p = 0.005), the number of oocytes retrieved
(p = 0.002), and number of fertilized oocytes (p < 0.0001).
There were no significant differences in basal FSH,
number of gonadotropin units (rFSH) consumed and
peak E2 and P on the day of oocyte retrieval among the
three groups. The use of a GnRHa long protocol or a
GnRH antagonist protocol did not alter the hormonal
profile dynamics, the E2/P ratio or clinical pregnancy rate.
Serum (luteal) hormonal parameters at different days of
ET (OI +4 days, OI +5 days and OI +7 days) and derived
E2/P ratio for clinical pregnancies, preclinical abortions,
and non-pregnant cycles are summarized in Table 2.
Women with clinical pregnancies had significant higher
mean E2/P ratios on OI +4 days (p = 0.01), OI +5 days (p
= 0.005) and OI +7 days (p = 0.0001) compared with
those who had either a preclinical abortion or failed to
conceive (Table 2). Interestingly, mean serum P was
higher in women with preclinical abortions compared to
clinical pregnancies or non-pregnant cycles, but it did not
reach statistical significance.
To analyze the prognostic power of E2/P ratio as measured
on OI +4 days, OI +5 days and OI +7 days with respect to
clinical pregnancy, the AUCROC was determined with ROC
analysis (Figure 1). The area under the curve suggests a
relationship between E2/P ratio on OI +4 days (0.70; 95%
CI = 0.60–0.80; p = 0.003), on OI +5 days (0.76; 95% CI
= 0.64–0.88; p = 0.001) and on OI +7 days (0.85; 95% CI
= 0.75–0.96; p < 0.0001) and the clinical pregnancy rate.
Discussion
For normal endometrial morphology to occur, an E2 prim-
ing phase is required followed by P. In the pre-GnRH ago-
nist era, the alteration of the E2/P ratio was considered a
main cause of luteal-phase inadequacy and IVF failure,
possibly mediated by the luteolytic action of E2 [12]. The
action of estrogen is required for up-regulation of P recep-
tors. In the follicular and early luteal phases of a normal
menstrual cycle, both E2and P receptors are found in glan-
dular and stromal compartements [13]. P antagonizes the
proliferative effects of E2 on the endometrial glands by
down-regulating estrogen receptors and is followed by a
subsequent disappearance of P receptors [14].
Many stimulation cycles in assisted reproduction are asso-
ciated with failed pregnancy despite the transfer of appar-
ently healthy and morphologically normal embryos. This
suggests impairment of endometrial differentiation or
receptivity in response to E2 and P may also warrant con-
Table 1: Comparison between different parameters for clinical pregnancies, preclinical abortions and non-conception cycles.
Clinical pregnancies Preclinical abortions Not pregnant P valuea
(n = 49) (n = 27) (n = 163)
Age (y) 32.2 ± 3.6 30.8 ± 3.3 33.1 ± 4.0 <0.05
Basal FSH (IU/L) 7.0 ± 2.6 7.2 ± 3.1 7.5 ± 2.5 NS
Peak estradiol (pg/mL) 1325 ± 816 1110 ± 586 1143 ± 864 NS
Peak progesterone (ng/mL) 8.5 ± 5 10.1 ± 6.2 8.2 ± 6.0 NS
No. oocytes/patient 10.7 ± 6.4 10.7 ± 5.7 7.9 ± 5.8 <0.05
Duration of stimulation 9.8 ± 1.3 9.8 ± 1.1 10.3 ± 1.4 NS
No. oocytes/fertilized 7.3 ± 4.3 6.9 ± 4.3 4.7 ± 3.6 <.001
No. embryo transfer 2.8 ± 0.4 2.7 ± 0.4 2.4 ± 0.9 NS
rFSH dosage (ampoules) 26.6 ± 6.8 31.4 ± 8.0 30.8 ± 10.4 NS
Note: Values are means ± SD. NS = not significant.
a For the three groups (Kruskal-Wallis test).Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1 http://www.jexpclinassistreprod.com/content/4/1/1
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sideration [15]. In our study, the role of the E2/P ratio at
the time of embryo transfer was compared with the preg-
nancy outcome. Our working hypothesis of this investiga-
tion is that a high P level in combination with a low E2
level in the early luteal phase could presage failed implan-
tation. These data suggest that the E2/P ratio on OI +4
days, OI +5 days and OI +7 days are significantly associ-
ated with clinical pregnancy rate. Interestingly, a signifi-
cant higher clinical pregnancy rate could be achieved if
blastocysts on OI +7 days were transferred. It seems that,
blastocyst transfer allowed the identification of embryos
with very high implantation potential [16], and probably
a better blastocyst-endometrial epithelium interaction.
The behaviour of the blastocyst may be influenced by sig-
nals from the endometrium which has been primed with
preimplantation ovarian steroids [17].
Specifically, we identified no differences in peak E2 and P
on day of oocyte retrieval or in the early luteal (on OI +4
days, OI +5 days and OI +7 days) E2 and P concentrations
between pregnant and non-pregnant women. The use of a
single luteal E2 and P measurement to predict endometrial
receptivity was not useful, although at our center the early
detection of a low E2 level did help identify those who
were then given supplementary hCG support for corpus
luteum rescue. Additionally, a single P value in the early
luteal phase was not informative for diagnosing luteal
phase defect. Assessment of the E2/P ratio in the early
luteal phase provided better prognostic information with
relatively higher values of this ratio being associated with
a healthy corpus luteum activity and successful implanta-
tion.
In this study, patients received both GnRH-agonist and
GnRH-antagonist stimulated cycles for controlled ovarian
hyperstimulation to prevent premature LH surge. Uni-
form luteal support consisting of vaginal micronized pro-
gesterone starting on the day of ET was given to all
patients in order to compensate for possible iatrogenic
luteal phase defect [18]. GnRH- agonists are associated
with persistent blockage of LH output for at least 10 days
following the final dose [2,19]. Prolonged administration
of GnRH agonists may also affect ovarian steroidgenesis
directly because of the presence of GnRH receptors in the
ovary [20]. In contrast, an inhibitory effect of GnRH-
antagonist on steroidgenesis may also be postulated
[21,22]. Here, we confirmed the present hormonal profile
dynamics, and the calculated E2/P ratio was not affected
by the treatment protocol used (GnRH agonist vs. antago-
nist), findings that agree with previous work [23].
Conclusion
We conclude that moderately increased P values in the
early luteal phase was associated with higher E2/P ratios
and better pregnancy outcomes, whereas a high increase
in P values in combination with a decrease in E2values
(reflected by a low E2/P ratio) append to indicate poor
reproductive outcome. Consequently, this retrospective
study implies that in the latter setting the embryo will
encounter a poorly receptive endometrium on the day of
transfer, resulting in impaired implantation.
To our knowledge, this is the first study specifically evalu-
ating E2/P ratio in relation to IVF outcome. Further study
is needed to examine whether the E2/P ratios could be
used as a prognostic test to predict which women will
have a clinical pregnancy in the setting of advanced repro-
ductive technologies following a COH.
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Table 2: Luteal phase characteristics of E2, P and the E2/P ratio of clinical pregnancies, preclinical abortions and non-pregnant cycles.
Clinical pregnancies Preclinical abortions Not pregnant P valuea
E2 on OI +4 days(pg/mL) 925.4 ± 634.8 792.0 ± 586.4 812.1 ± 794.5 NS
P on OI +4 days (ng/mL) 54.0 ± 24.9 68.6 ± 60.5 56.7 ± 34.4 NS
E2/P Ratio on OI +4 days 18.2 ± 11.5 10.3 ± 8.5 11.8 ± 10.0 0.010
E2 on OI +5 days (pg/mL) 1612.5 ± 1118.9 1210.4 ± 576.6 1257.4 ± 905.2 NS
P on OI +5 days (ng/mL) 101.4 ± 52.6 131.5 ± 66.6 110.6 ± 56.3 NS
E2/P Ratio on OI +5 days 18.1 ± 11.3 9.3 ± 6.3 8.7 ± 7.9 0.005
E2 on OI +7 days (pg/mL) 2416 ± 787.9 2456.5 ± 854.9 2032.0 ± 837.4 NS
P on OI +7 days (ng/mL) 170.9 ± 57.2 187.0 ± 28.2 198.5 ± 118.4 NS
E2/P Ratio on OI +7 days 15.4 ± 6.2 6.5 ± 7.6 5.8 ± 10.7 <0.001
Note: Values are means ± SD. NS = not significant. OI = ovulation induction.
a = For the three groups (Kruskal-Wallis test).Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1 http://www.jexpclinassistreprod.com/content/4/1/1
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